EnginZyme produces key mRNA vaccine ingredient using biocatalysis
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Dr. Karikó is the third Solvay Prize winner to become a Nobel Prize laureate
This production block consists of chemical synthesis reactions and clean rooms areas to produce final API
Proteolysis Targeting Chimeras (PROTACs) technology as potential new method for mosquito-borne disease control
Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
Subscribe To Our Newsletter & Stay Updated